In a year when medicine keeps asking how early a disease can be caught and how far a treatment can reach before it is too late, six-year results from an international trial have arrived in New Zealand with a quiet but weighty message. Adding the drug ribociclib, sold as Kisqali, to standard hormone therapy has been shown to lower the chance that early breast cancer returns and, more striking still, to reduce the risk of death. For the roughly one thousand New Zealand women each year whose cancer is found early but carries a lingering threat of relapse, the question now is whether a country's p
Ribociclib Cuts Early Breast Cancer Recurrence 26% and Improves Survival in Six-Year Global Study
A 19% lower risk of death, and a funding decision still pending
What's actually new here? The drug is already used in New Zealand.
It's funded for advanced disease. These are six-year results in early-stage patients, showing 26% lower recurrence risk and 19% lower risk of death alongside standard hormone therapy.
Why does the survival figure matter more than the recurrence one?
Recurrence is a serious event, but survival is the harder outcome to move. The researchers called it clinically meaningful, and the benefit kept growing after patients stopped the drug for around three years.
I'd keep one thing in view. These are the study's reported figures, presented at a congress, and the piece cites them without detailing the trial design or absolute numbers. A 19% lower risk of death is relative, not a count of lives.
And the advocates quoted?
Wilson, Shahbazpour and Burgess all welcome the results and want access widened. Burgess talks about the fear of recurrence lingering after treatment ends.
Worth noting that the advocacy groups are arguing for funding, so their statements are positions, not findings.
Where does funding stand?
Pharmac's advisory committee recommended funding for high-risk early disease in 2025. No final decision has been announced. Australia and England already fund it.
And the figure of around 900 people benefiting in five years is an expectation conditional on approval, not an observed number.
El Pulso
- Six years of data show ribociclib with hormone therapy cutting recurrence risk by 26% and death risk by 19% against hormone therapy alone.
- Roughly a thousand New Zealand women a year face the lingering fear that early breast cancer will return after treatment seems finished.
- Pharmac's advisory committee backed funding for high-risk early disease in 2025, yet no final decision has landed, and the wait weighs on patients.
- Patient advocates press for access to keep pace with research, arguing that treatment should follow clinical need rather than the ability to pay.
- Around 900 high-risk patients could benefit within five years if the funding decision turns in their favour, and all eyes are now on Pharmac.
In a year when medicine keeps asking how early a disease can be caught and how far a treatment can reach before it is too late, six-year results from an international trial have arrived in New Zealand with a quiet but weighty message. Adding the drug ribociclib, sold as Kisqali, to standard hormone therapy has been shown to lower the chance that early breast cancer returns and, more striking still, to reduce the risk of death. For the roughly one thousand New Zealand women each year whose cancer is found early but carries a lingering threat of relapse, the question now is whether a country's public purse will follow the evidence, as Australia and England have already chosen to do.
Six years of follow-up data on ribociclib, already used in New Zealand for more advanced breast cancer, have been presented at the European Society for Medical Oncology Congress in Madrid. The findings show that when the drug is added to standard hormone therapy for early disease, recurrence risk falls by 26% compared with hormone therapy alone. The result that has drawn the most attention is survival: women on the combination had a 19% lower risk of death, a benefit that continued to grow even after patients had stopped taking the medicine for around three years. The advantage held whether or not cancer had reached nearby lymph nodes, and no new safety concerns emerged.
For New Zealand, the numbers carry particular weight. About 3,700 women are diagnosed with breast cancer each year, and the disease remains the leading cause of cancer death in women under 65. Wāhine Māori and Pacific women die at almost twice the rate of other women. The subtype at the centre of this research, hormone receptor positive and HER2 negative, makes up most local diagnoses, and more than a thousand women a year are found at an early stage yet still face the possibility of relapse. Oncologist Dr Sheridan Wilson points out that once cancer spreads to distant organs, cure is rarely possible, which is why stopping recurrence at the start matters so much. She also speaks of the heavy psychological load that recurrence fear carries for patients.
Kisqali is publicly funded here for locally advanced or metastatic disease, but not for earlier stages. A Pharmac expert committee recommended funding for high-risk early disease in 2025, and about 900 people might benefit in the first five years, yet no final decision has been announced. Australia and England already fund it for eligible early-stage patients.
Patient groups are using the new data to press their case. Dr Mehdi Shahbazpour of Breast Cancer Foundation NZ argues that earlier treatment may do more than prevent recurrence and could help women live longer, and he calls for sustained investment in the medicines budget with priority for early-stage care. Libby Burgess of Breast Cancer Aotearoa Coalition says a wider group of women may benefit and that knowing more options exist can bring real reassurance to women and their families. For now, the decision that matters most is Pharmac's final word on funding.
Six years of follow-up data on a breast cancer drug already used in New Zealand have now been presented in Madrid, and the numbers are drawing attention from clinicians and patient groups at home. At the European Society for Medical Oncology Congress 2026, researchers reported that adding ribociclib, sold as Kisqali, to standard hormone therapy lowered the risk of early breast cancer coming back by 26% compared with hormone therapy alone.
The finding that stands out most is about survival. Women who received the combination had a 19% lower risk of death, which the researchers described as a clinically meaningful improvement in overall survival. The benefit kept growing over time, even though patients had been off the medication for a median of around three years. It was consistent in women with and without cancer in nearby lymph nodes, a key factor in judging how likely a recurrence is. With the longer follow-up, the safety profile matched earlier analyses and no new safety signals appeared.
The stakes in New Zealand are high. Around 3,700 women are diagnosed with breast cancer here each year, one in ten New Zealand women over a lifetime, a rate among the highest in the OECD. It remains the leading cause of cancer death in women under 65. Wāhine Māori and Pacific women with the disease die at almost twice the rate of non-Māori, non-Pacific women.
The subtype in question is hormone receptor positive, HER2 negative, which accounts for 74% of New Zealand diagnoses. More than 1,000 women a year are diagnosed with it at an early stage but still face a risk of relapse, close to a third of all breast cancer diagnoses. Research cited in the report shows that 20% to 40% of patients with stage II or III disease have a recurrence or other significant health event within five years, rising to roughly 40% to 60% within ten.
Dr Sheridan Wilson, a New Zealand medical oncologist, says that once breast cancer spreads to distant organs, cure is rarely possible, so improving early treatment to prevent recurrence matters. She also points to the psychological weight recurrence risk places on patients, and says more effective options give more women the chance at long, cancer-free lives.
Kisqali is publicly funded in New Zealand for locally advanced or metastatic breast cancer, but not for earlier-stage disease. In 2025 a Pharmac expert advisory committee recommended funding it for high-risk early breast cancer, but no final decision has been announced. It is already publicly funded for eligible early-stage patients in Australia and England. Around 900 people with high-risk early-stage (N2) disease would be expected to benefit in the first five years if funding were approved.
Patient groups are using the data to press the case. Dr Mehdi Shahbazpour of Breast Cancer Foundation NZ says the results suggest earlier treatment may do more than prevent recurrence; it may help women live longer. He argues access must keep pace with research, that treatment decisions should rest on clinical need rather than ability to pay, and that the medicines budget needs sustained investment, with priority for early-stage treatments.
Libby Burgess, chair of Breast Cancer Aotearoa Coalition, says the results suggest a wider group of women could benefit, and notes that fear of recurrence can linger long after treatment ends. Knowing further options exist, she says, can bring reassurance to women and their families.
The thing to watch now is Pharmac's final decision on funding for high-risk early breast cancer.
Citas Notables
When breast cancer spreads to distant organs, curative therapy is rarely achievable, so improving early-stage treatment remains imperative.— Dr Sheridan Wilson, medical oncologist
Access to treatment needs to keep pace with advances in research.— Dr Mehdi Shahbazpour, Breast Cancer Foundation NZ